JP2016504046A5 - - Google Patents

Download PDF

Info

Publication number
JP2016504046A5
JP2016504046A5 JP2015552899A JP2015552899A JP2016504046A5 JP 2016504046 A5 JP2016504046 A5 JP 2016504046A5 JP 2015552899 A JP2015552899 A JP 2015552899A JP 2015552899 A JP2015552899 A JP 2015552899A JP 2016504046 A5 JP2016504046 A5 JP 2016504046A5
Authority
JP
Japan
Prior art keywords
modified
egfr
oligonucleotide
sequence
modified sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015552899A
Other languages
English (en)
Japanese (ja)
Other versions
JP6574136B2 (ja
JP2016504046A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/011496 external-priority patent/WO2014110577A1/en
Publication of JP2016504046A publication Critical patent/JP2016504046A/ja
Publication of JP2016504046A5 publication Critical patent/JP2016504046A5/ja
Application granted granted Critical
Publication of JP6574136B2 publication Critical patent/JP6574136B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015552899A 2013-01-14 2014-01-14 Ｅｇｆｒの発現をサイレンシングするためのｄｎａザイム Expired - Fee Related JP6574136B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361752117P 2013-01-14 2013-01-14
US61/752,117 2013-01-14
PCT/US2014/011496 WO2014110577A1 (en) 2013-01-14 2014-01-14 Dnazyme for silencing the expression of egfr

Publications (3)

Publication Number Publication Date
JP2016504046A JP2016504046A (ja) 2016-02-12
JP2016504046A5 true JP2016504046A5 (enExample) 2017-02-09
JP6574136B2 JP6574136B2 (ja) 2019-09-18

Family

ID=51167450

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015552899A Expired - Fee Related JP6574136B2 (ja) 2013-01-14 2014-01-14 Ｅｇｆｒの発現をサイレンシングするためのｄｎａザイム

Country Status (7)

Country Link
US (1) US9856480B2 (enExample)
EP (1) EP2943578B1 (enExample)
JP (1) JP6574136B2 (enExample)
KR (1) KR20150136588A (enExample)
CN (1) CN105264084A (enExample)
CA (1) CA2898200A1 (enExample)
WO (1) WO2014110577A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220061311A1 (en) * 2018-11-05 2022-03-03 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for reducing cryopreservation toxicity
IL302594A (en) * 2020-11-09 2023-07-01 1E Therapeutics Ltd Catalytic sequence based methods of treating or preventing bacterial infections
CN116286831B (zh) * 2023-01-29 2024-02-20 珠海市人民医院 靶向egfr t790m突变体的核酸适配体及其在制备治疗肺癌药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040031072A1 (en) * 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US7365185B2 (en) * 2000-07-19 2008-04-29 Monsanto Technology Llc Genomic plant sequences and uses thereof
AU3497701A (en) * 2000-02-08 2001-08-20 Ribozyme Pharmaceuticals, Inc. Nucleozymes with endonuclease activity
EP1767632A3 (en) * 2001-05-29 2009-12-30 Sirna Therpeutics, Inc. A method for local administration of synthetic double-stranded oligonucleotides targeting a VEGF receptor
US6890719B2 (en) * 2002-05-10 2005-05-10 The Board Of Trustess Of The University Of Illinois Fluorescence based biosensor
GB0224663D0 (en) * 2002-10-23 2002-12-04 Isis Innovation DNAzyme
WO2005108570A1 (ja) * 2004-05-11 2005-11-17 National University Corporation Yokohama National University 核酸酵素複合体
EP1766068A4 (en) * 2004-06-04 2010-03-03 Genentech Inc EGFR Mutations
BRPI0607235A2 (pt) * 2005-02-24 2009-08-25 Amgen Inc mutações do receptor do fator de crescimento epidérmico
CA2683559C (en) 2007-04-13 2019-09-24 Dana Farber Cancer Institute, Inc. Methods for treating cancer resistant to erbb therapeutics
CN103080314B (zh) * 2010-09-30 2016-04-13 Lsip基金运营联合公司 显性突变基因表达抑制剂

Similar Documents

Publication Publication Date Title
KR102129636B1 (ko) Pd-l1 축 결합 길항제 및 vegf 길항제를 사용하여 암을 치료하는 방법
JP5719322B2 (ja) 腫瘍の治療
Atreya et al. Systemic therapy for metastatic colorectal cancer: from current standards to future molecular targeted approaches
JP2017101072A (ja) ホスファチジルイノシトール−３−キナーゼ経路バイオマーカー
TW201022214A (en) Treatment method
US11820813B2 (en) Anti-neurotensin long fragment antibodies and uses thereof
DE602007007985D1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
TW201032796A (en) Treatment of lung cancer with a PARP inhibitor in combination with a growth factor inhibitor
CN106687135A (zh) 使用pd‑1轴结合拮抗剂和il‑17结合拮抗剂治疗癌症的方法
CN107427501B (zh) 通过联合使用治疗癌症的方法
von Achenbach et al. Epidermal growth factor receptor and ligand family expression and activity in glioblastoma
TW202129013A (zh) 偵測編碼新生抗原之融合基因之方法
JP2024041781A (ja) チロシンキナーゼ阻害剤と併用してｅｇｆ／ｅｇｆｒ経路を抑制する方法および組成物
US20190151346A1 (en) Combinations therapies for the treatment of cancer
Kjær et al. Cetuximab resistance in squamous carcinomas of the upper aerodigestive tract is driven by receptor tyrosine kinase plasticity: potential for mAb mixtures
JP2016504046A5 (enExample)
US10077303B2 (en) Anti-neurotensin antibodies and uses thereof
JP2022527499A (ja) Ｈｅｒ２エクソン２１挿入を有するがん細胞に対する抗腫瘍活性を有する化合物
JP2014525270A5 (enExample)
Zhang et al. Recent trend for egfr-based and alk-based targets: A patent analysis
JP2023507751A (ja) 膵臓がんの治療および予後
US20230321087A1 (en) Fgfr inhibitor combination therapies
US12351878B2 (en) Identification of HER2 mutations in lung cancer and methods of treatment
HK40097045A (zh) 治疗组合物用於治疗上皮源性肿瘤患者的用途
Observation et al. 6 Neoplastic Disease